RCEL
Live chart
What they do
AVITA Medical, Inc. operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device.
For information only · Important disclosures
Grades vs sector
No sector grades for RCEL yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.99 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.42 vs trailing $-1.43. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score -10.7 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $71.6M | $-48.6M | $-32.2M |
| 2024 | $64.3M | $-61.8M | $-58.1M |
| 2023 | $50.1M | $-35.4M | $-39.4M |
| 2022 | $34.4M | $-26.7M | $-19.5M |
| 2021 | $29.2M | $-26.6M | $-26.8M |
| 2020 | $14.3M | $-42.0M | $-23.3M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +27.7%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.39 | -0.36 | +7.9% |
| 2026-05-14 | -0.38 | -0.48 | -27.3% |
| 2026-02-12 | -0.55 | -0.54 | +2.8% |
| 2025-11-06 | -0.46 | -0.71 | -56.3% |
| 2025-08-07 | -0.36 | -0.58 | -63.2% |
| 2025-05-08 | -0.51 | -0.83 | -60.7% |
| 2025-02-13 | -0.74 | -0.70 | +6.1% |
| 2024-11-07 | -0.69 | -0.93 | -34.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $21.7M | +17.8% |
| 2026-03-31 | $19.3M | – |
| 2025-12-31 | $17.6M | – |
| 2025-09-30 | $17.1M | – |
| 2025-06-30 | $18.4M | – |
Analyst actions
PT $15
PT $12
PT $14
PT $11
PT $7
PT $6
Stats refreshed 2026-10-21 13:44:04 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026